Genital Atrophy Common, Rapid After HT Stopped

BY MICHELE G. SULLIVAN
Mid-Atlantic Bureau

WHITE SULPHUR SPRINGS, W.VA. — Within just 6-12 months of discontinuing hormone therapy, more than 96% of postmenopausal women will show altered vaginal pH, a marker for tissue change and its associated genital atrophy, Murray Freedman, M.D., reported.

Within just 6-12 months of discontinuing hormone therapy (HT), more than 96% of postmenopausal women will show altered vaginal pH, a marker for tissue change and its associated genital atrophy, a clinical professor of ob/gyn at the Medical College of Georgia in Augusta.

The rest of the women had both elevated vaginal pH and decreased serum estradiol. The most common clinical finding in the study was involution of the vulvar structures and a rapidly occurring introital stenosis, which correlated with frequent complaints of dyspareunia, Dr. Freedman noted at the annual meeting of the South Atlantic Association of Obstetricians and Gynecologists.

Because the onset of genital atrophy is insidious and its measurement subjective, the number who experienced it was “hard to quantify,” Dr. Freedman told this newspaper. “There is no real measurement for it. But for many of these women, the stenosis became noticeable within 6-12 months.”

His observations led him to conclude that the dyspareunia many postmenopausal women experience has more to do with introital stenosis than vaginal dryness. “The dryness was secondary to the stenosis and its associated vaginal atrophy. Once you got past the introitus, the upper vagina was uninvolved.”

His prospective observational study, which evaluated 300 women who discontinued HT after publication of the initial Women’s Health Initiative results in July 2002, all underwent a pelvic exam and had their vaginal pH tested within 12 months of therapy discontinuation (most within 6 months). Those with a normal vaginal pH level (4.5 or below) had their serum estradiol level evaluated.

The vast majority of the women (290) had a pH level of more than 4.5. Only 10 maintained a normal vaginal pH. Three of those women had serum estradiol of less than 20 pg/mL, consistent with postmenopausal status.

The other seven had normal estradiol levels. One of these was a 50-year-old woman with her uterus intact, who had been placed on HT for menopausal symptoms. The other six women were older (57-76 years) and either overweight or obese.

In addition to observing introital stenosis, he also noted that the urethral meatus became more prominent in many women, assuming almost a tubular form and expanding to constitute up to two-thirds of the introitus. This is not surprising, he said, because the urethra and trigone are just as heavily endowed with estrogen receptors as the lower vagina and vulva and just as susceptible to involutional change associated with estrogen depletion.

“Embryologically, the vulva, distal vagina, trigone, and urethra are all derived from the urogenital sinus and contain the highest concentration of estrogen receptors. The upper vagina is actually a downward growth of the müllerian system” and so less susceptible to change associated with estrogen depletion.

Because genital atrophy is so widespread and rapid after menopause in the absence of HT, women should be proactively counseled about how to maintain good genital health, Dr. Freedman said. If the decision is made to discontinue HT, topical estrogen can prevent genital atrophy and, if administered within the first year of estrogen cessation, can even reverse some changes.

Dr. Freedman noted that most physicians—especially males—never broach the subject of sexuality with their postmenopausal patients. “To those men, I would put this question: ‘At what age would you like your genitalia to begin shrinking?’” Dr. Freedman said. “I bet it wouldn’t be 51, which is the average age of menopause in this country.”